Indolactam Dipeptides as Nanomolar Gli Inhibitors

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Gli transcription factors in the Hedgehog (Hh) pathway are crucial for development.
• Reactivated Gli proteins in adult tissues promote tumorigenesis, particularly in basal cell carcinomas.

Purpose of the Study:

• To develop novel indolactam dipeptides targeting protein kinase C (PKC) as regulators of Gli.
• To evaluate the efficacy of these compounds in inhibiting Gli-dependent cancers.

Main Methods:

• Synthesized a series of indolactam dipeptides, including analogues of (-)-pendolmycin.
• Utilized Gli reporter assays to assess compound activity.
• Tested lead compounds in Gli-dependent basal cell carcinoma cell models.

Main Results:

• Identified N-hexylindolactam V as a potent Gli suppressor.
• Demonstrated superior Gli suppression compared to existing clinical inhibitors.
• Showcased the ability of N-hexylindolactam V to inhibit basal cell carcinoma cell growth.

Conclusions:

• Novel indolactam dipeptides targeting PKC offer a promising strategy for Gli antagonist development.
• These findings open new therapeutic avenues for combating Gli-driven cancers.
• Structure-activity relationship studies guide the design of future Gli inhibitors.